Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL32P22 is a processed pseudogene related to the ribosomal protein L32 (RPL32) gene family. Unlike the functional RPL32 gene, which encodes a protein component of the large (60S) ribosomal subunit involved in protein synthesis[1][4], RPL32P22 does not produce a functional protein and has no known physiological role[3]. There are multiple RPL32-related pseudogenes across the genome, but none of these—including RPL32P22—are considered drug targets or used for therapeutic interventions[1][3][4]. Some pseudogenes from the RPL32 family (e.g., RPL32P3) can have regulatory functions in specific contexts, but there is no evidence that RPL32P22 itself plays such a role[7]. RPL32P22 is not implicated in any disease or clinical context, and there are no drugs, mechanisms of action, or biomarkers associated with it[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ribosomal protein L32 pseudogene 22 (RPL32P22).